Navigation Links
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Date:4/23/2008

e onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.(7)

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.(12)

Notes to editors

About VYVANSE

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if you or your child develops symptoms that suggest heart problems, such as chest pain or fainting.

VYVANSE should not be taken if you or your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking VYVANSE if you or your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if you or your child develops any of these conditions or symptoms while taking VYVANSE.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
2. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
3. Medicare Approves in Home Sleep Apnea Testing
4. 3SBio Inc. Approves Share Repurchase Program
5. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
6. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
7. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
8. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
9. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
10. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PHILADELPHIA , Sept. 2, 2014  TransCelerate ... developed a recommended approach for protecting personal data ... with researchers, patients and others. The document describes ... personal information from CSRs and other related clinical ... The goal of the TransCelerate CSR ...
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
(Date:9/2/2014)... 02, 2014 PMG Research, Inc ... clinical research site: PMG Research of Rocky Mount. Effective ... of the clinical research department at Boice-Willis Clinic ... in eastern North Carolina. This new site enhances PMG’s ... in Rocky Mount and the surrounding communities, this brings ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... Cell Technologies, Inc., a leader in adult stem cell research and ... Stemedica,s Scientific Advisory Board. In this capacity, she will help ... and cellular delivery system for burn and wound management. , ... ...
... the American Society of Clinical Oncology (ASCO) annual meeting, May ... at 5:00 p.m. Eastern Time - REDWOOD CITY, Calif., April ... today announced that the QUASAR validation study met its ... II colon cancer patients following surgery, and that the colon ...
... and CAMBRIDGE, Mass., April 14 ( AACR ... Genstruct Inc. , a systems biology company focused ... develop novel therapeutics, molecular diagnostics and patient-specific therapies, today ... one of its top pharmaceutical partners will be presented ...
Cached Biology Technology:Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 2Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 3Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 4Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 4Genstruct to Present Results of Collaboration with Top Pharmaceutical Company at American Association for Cancer Research's Annual Meeting 2
(Date:9/2/2014)... of Human Genetics (ASHG) and the National Human ... Institutes of Health, have named Elizabeth P. Tuck, ... School in Columbus, Ohio, the first ASHG/NHGRI Genetics ... , The Genetics and Education Fellowship is intended ... experience, and network to prepare for a career ...
(Date:9/2/2014)... of Evolutionary Biology study provides evidence that ... diversification. , Investigators argue that the same factor ... Galpagos Islands is also responsible for the linguistic ... barriers that impede interaction between speech communities. Therefore, ... due to a reduction of linguistic contact. , ...
(Date:9/2/2014)... sequence their genetic information. How is it possible ... parts of the body are so different? While every ... additional regulatory layer exists that determines which of the ... modifications of genome-bound histone proteins or the DNA itself ... top of the genetic information and is thus called ...
Breaking Biology News(10 mins):ASHG and NHGRI award first genetics and education fellowship 2Throwing a loop to silence gene expression 2
... the momentum of,September,s impressive showing at the ePassports EAC ... ) advances its role as the,world,s ePassport leader by ... to advanced second-generation ePassports based on the,Extended Access Control ... "Second-generation ePassports represent the beginning of an evolution that,will ...
... WALNUT CREEK, Calif. The U.S. Department of Energy Joint ... assembly of the soybean (Glycine max) genetic code, making ... new breeding strategies for one of the world,s most ... 70 percent of the world,s edible protein, but also ...
... as an homage to achievement in the field of coral ... link between corals of the Pacific and Atlantic. Dr. Ann ... McNeill of the University of Miami named a new species ... some six million years old after renowned coral reef ...
Cached Biology News:The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 2The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 3The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 4DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Isopora or isn't it? 2
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
... 100 g monoclonal antibody which can ... V from heart mitochondria. Also included are ... control immunocapture. The Complex V immunocapture kit ... (E.C. 3.6.3.14) from small amounts of tissue. ...
Biology Products: